<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Levels of neuron-specific enolase (NSE), a glycolytic enzyme localized in neurons, were measured in serum and cerebrospinal fluid (CSF) of patients with early-<z:hpo ids='HP_0003674'>onset</z:hpo> (e-AD) and <z:hpo ids='HP_0003584'>late-onset</z:hpo> (l-AD) <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD) and controls </plain></SENT>
<SENT sid="1" pm="."><plain>Mean CSF NSE levels in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> did not significantly differ from those in controls, although in the AD group a correlation was found between NSE levels and severity of <z:hpo ids='HP_0100543'>cognitive deficits</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In VD patients, CSF NSE was lower than in controls or in AD patients </plain></SENT>
<SENT sid="3" pm="."><plain>These findings are of physiopathological interest but suggest that CSF NSE is not a useful biological marker in <z:hpo ids='HP_0000726'>dementia</z:hpo> disorders </plain></SENT>
</text></document>